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ABSTRACT 
Despite efforts made to improve the availability of suitably licensed and manufactured drug 
products for children, the gap between supply and demand is still wide. Suitable dosage forms 
formulated at many different strengths by including harmless excipients would be needed to 
medicate children of different ages. Therefore, extemporaneously prepared products are still 
required to ensure that accurate doses and suitable dosage forms are available for children’s 
drug therapy. Extemporaneously prepared products are produced mainly in hospital and 
community pharmacies. 
 
The use of extemporaneous preparations can be considered as unlicensed drug use and these 
raise concerns about quality, stability, bioavailability, efficacy and safety. Currently, there are 
no appropriate and comprehensive published standards, and thus decisions in different steps 
of preparation process have to be done by applying professional pharmaceutical skills. The 
uniformity of content, selection of safe excipients and stability issues are part of the main 
challenges faced in the preparation of extemporaneous drug products.  
 
The present study examined the chemical stabilities and content uniformities of 
extemporaneously prepared nifedipine oral dosage forms to be used in newborns and infants. 
In addition, physical and microbiological stability of the suspension preparations was 
assessed. Individually weighed oral powders, manually filled capsules and unit dose syringes 
were prepared either by using nifedipine drug powder or a crushed commercial tablet. A 
reproducible and validated stability-indicating high performance liquid chromatography method 
was developed in order to measure nifedipine concentrations and to assay the 
photodegradation of nifedipine. 
 
The results indicate that both solid and liquid oral dosage forms may provide suitable solutions 
to treat newborns and infants. The content uniformities of the nifedipine suspensions, powders 
and capsules met the requirements of the European Pharmacopoeia. Due to the light 
sensitivity of nifedipine, it required handling in dimly lit room and storage protected from light. 
When exposed to light, 20–30% photodegradation occurred within three hours. 
 
Nifedipine unit dose suspensions formulated with hypromellose 1% and packaged in capped 
syringes were found suitable also for nasogastric administration through feeding tubes. The 
nifedipine suspensions were stable over the four week study period. Autoclaved drug-free 
hypromellose 1.0% solutions were stable for at least 6 months. 
 
It was found that the total mass of the nifedipine unit powder prepared with lactose 
monohydrate or microcrystalline cellulose had to be 300 mg or more to ensure accurate 
dosage and to prevent significant drug loss. When the mass was 100 mg or 50 mg, the 
nifedipine amount was less than 80% of the theoretical value. Three quarters of the missing 
amount was located on the emptied powder papers. Oral powders were stable for up to one 
year. Nifedipine capsules, whose contents were simply emptied prior to use, were faster to 
prepare and when comparing the quality, do represent an alternative to oral powders. 
Nifedipine recovery remained acceptable in all three sizes of emptied capsules.  
 
In conclusion, nifedipine oral powders and suspensions were stable throughout the study 
periods when protected from light, whereas on exposure to light, nifedipine degraded rapidly. 
Content uniformities of the formulated nifedipine oral preparations met the established 
requirements. However, the loss of nifedipine was significant, especially in oral powders with 
low total weights. Thus, nifedipine capsules represent an alternative to oral powders in 
preparing paediatric medications. 
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GLOSSARY  
 
 
 
 
EXTEMPORANEOUS PREPARATION 
 
A product, which is dispensed immediately after 
preparation and not kept in stock (Pharmaceutical 
Inspection Convention, 2008) 
 
INFANT AND TODDLER 
 
Age range from 28 days to 23 months (Costello et 
al., 2007) 
 
OFF LABEL USE OF DRUGS Defined by FDA: “Use for indication, dosage form, 
dose regimen, population or other use parameter 
not mentioned in the approved labelling.” 
(European Society of Clinical Pharmacy, 2008) 
 
An agreed definition is still under discussion in 
Europe (TEDDY, 2007) 
 
PRETERM NEWBORN INFANT 
 
Born before 37 weeks’ gestation (Costello et al., 
2007) 
 
‘SPECIALS’ 
 
Extemporaneous preparations that are made in 
larger volumes by licensed manufacturers 
(Costello et al., 2007) 
 
TERM NEWBORN INFANT 
 
Age range from 0 days to 27 days (Costello et al., 
2007) 
 
UNLICENSED USE OF DRUGS 
 
Unlicensed use includes: modifications to licensed 
drugs, drugs that are licensed but the particular 
formulation is manufactured under a special 
licence, new drugs available under a special 
manufacturing licence, use of chemicals as drugs, 
drugs used before a licence has been granted, 
and imported drugs (Turner et al., 1998) 
 
An agreed definition is still under discussion in 
Europe (TEDDY, 2007) 
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1 INTRODUCTION 
 
“Parents should be taught how to administer their infant’s drugs and then encouraged to 
do so whenever possible.” “Infants should be spoken to softly and in high-pitched tones. 
They should be handled gently and should be held and cuddled before and after 
administration” (Pagliaro, 2002).  
 
Unfortunately, only a few products have been designed and tested specifically for 
paediatric use (Costello et al., 2007; Pawar and Kumar, 2002). However, the situation is 
hopefully going to change in European Union (EU). The aim of the EU Paediatric 
Regulation (2007) is to promote safer medicines for children for example by development 
and availability of medicines and by ensuring that medicines for use in children are of high 
quality, ethically researched, and appropriately authorised (EMEA, 2008). In addition, 
paediatric medicinal products is one focus area in National Agency for Medicines (NAM) in 
Finland (National Agency for Medicines, 2008a).  
 
The lack of appropriate paediatric formulations is a worldwide problem (Giacoia et al., 
2007a). Pharmaceutical companies manufacture special preparations for paediatric 
patients mainly if the products are likely to be marketable and will generate profit for the 
manufacturer (Pawar and Kumar, 2002). The range of doses used may be wide for 
paediatric patients, because of the developmental changes that occur during a child 
lifetime (Costello et al., 2007). Of all the active substances that were licensed by the 
European Agency for the Evaluation of Medicinal Products (EMEA) in the period October 
1995 to September 2005, only 33% were licensed for paediatric use, 23% for use in 
infants and only 9% in newborns (Ceci et al., 2006). Since many drugs are not labelled for 
use in paediatric populations, the manufacturer does not usually market suitable dosage 
forms for children, e.g. a liquid dosage formulation (Pai and Nahata, 2001). 
 
Therapeutic advances (e.g. modified-release forms) are rarely available for children. 
Expertise and facilities in hospital pharmacies limit the preparation of modern dosage 
forms, but pharmaceutical companies have appropriate facilities and should be 
encouraged to make them available for children (Brion et al., 2003). 
 
The reasons mentioned for the absence of approved prescribing information and specific 
dosage forms for children include difficulties in evaluating the safety and efficacy of 
medicines (Giam and McLachlan, 2008). There are problems with recruiting children for 
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clinical trials and ethical considerations if invasive procedures need to be performed. 
Clinical trials for several different age groups are perceived as expensive. Suitable 
paediatric formulation requires further development and testing. Markets for children’s 
medicines tend to be small and this impacts significantly on commercial decisions. This 
lack of suitable dosage forms for use in paediatric patients is a contributor to the 
widespread need for extemporaneous preparations. Extemporaneous preparations are 
prepared mainly in hospital and community pharmacies. 
 
In this licentiate thesis, the extemporaneous preparation of oral paediatric formulations is 
examined. In the literature review, the prevalence and quality of extemporaneous 
preparations are discussed as well as some technological and stability aspects in oral 
formulations to the extent to which the relate to the aims of this study. In the experimental 
part of this work, three essential oral dosage forms were investigated: oral powders, 
capsules and suspensions. A calcium channel blocker, nifedipine, was chosen as a 
problem drug substance both due to its chemical properties, which are insolubility in water 
and sensitivity to light and constant off-label and unlicensed use in the paediatric 
population, also in preterm newborn infants. Pulmonary hypertension and 
bronchopulmonary dysplasia are treated with extemporaneously prepared nifedipine 
products because no suitable dosage form is marketed. This study is restricted to preterm 
newborn infants, term newborn infants, infants and toddlers (Costello et al., 2007). 
Children over 2 years old and adolescents up to 18 years of age are excluded.  
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2 REVIEW OF THE LITERATURE 
 
2.1 Use of off-label and unlicensed medicines 
 
Many medicines licensed for use in adults are not licensed for use in infants even though 
their use may be accepted as the current standard of care (Giam and McLachlan, 2008). 
In the absence of specific clinical trial-based data in children, clinicians are forced to rely 
on results of studies conducted in adults, although children have different metabolism to 
adults and their response to medicines can be unpredictable (‘t Jong et al., 2001). This 
represents an ethical difficulty for the clinician: to prescribe a medicine for which there is 
not enough safety data or to avoid its use thus depriving a child of the potential 
therapeutic benefits. Prescription, dispensing and administration of unlicensed and off-
label medicines are allowed by legislation in most countries, including EU countries (Giam 
and McLachlan, 2008). 
 
Many children are treated with unlicensed medicines or adult’s medicines used off-label. 
In a prospective study in neonatal intensive care unit (NICU), general paediatric ward and 
paediatric surgical ward in Kuopio University hospital (KUH) it was found that of all 
prescriptions (n=629), 51% were for licensed drugs, 36% for off-label use and 13% for 
unlicensed drugs (Lindell-Osuagwu et al, submitted). Most of the prescriptions for 
unlicensed drugs, 71%, were used in the NICU. This is evidently due to lack of suitable 
formulations of drugs for use in pre-term and term neonates and infants. According to 
Lindell-Osuagwu et al. (submitted), the overall proportion of prescriptions for unlicensed 
drugs (13%) was similar to that in other studies (10–12%) in paediatric intensive care units 
in France, Australia, Brazil and Italy. The most frequent reason for prescriptions of 
unlicensed drugs was the modifications of licensed drugs. The age groups most 
commonly receiving unlicensed drugs were neonates, infants and children less than 2 
years old. 
2.1.1 Problems with off-label and unlicensed drug use 
 
Drug products intended for adults are often not available in a concentration low enough for 
accurate and precise measurement of small doses (Nahata, 1999). Concentrated liquid 
and solid oral dosage forms may be associated with irritating effects on the 
gastrointestinal system, resulting in nausea, vomiting, or diarrhoea (Pagliaro, 2002). 
Errors may occur in measuring doses under 0.1 ml (Nahata, 1999). Measurement errors 
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with potent drugs like morphine and digoxin have been reported to cause intoxication in 
paediatric patients. If one wishes to achieve an appropriate strength, then it may 
sometimes be necessary to dilute the concentrated commercial preparations, a practice 
which may also render the preservatives ineffective (Costello et al., 2007; Nahata, 1999). 
Many cases of tenfold dosing error in children have been reported in the literature and 
several have resulted in tragic outcomes, thus, each step of a calculation should be 
written to permit double checking (Costello et al., 2007). 
 
The lack of suitably adapted medicines and calculated individualized doses for children 
may increase the risk of adverse reactions and ineffective treatment (under- or over-
dosing) (Costello et al., 2007; Pagliaro, 2002). Unsuitable formulations and routes of 
administration and the use of extemporaneous or officinal formulations to treat the 
paediatric population may be of poor quality (Regulation (EC) No 1901/2006). There is 
elevated risk in newborn infants, because they are more likely to be predisposed to 
adverse drug reactions due to their physiological immaturity (Costello et al., 2007). Most 
doses for children are based on weight, although body surface area may reflect the 
physiological differences more accurately. There is a wide variation in body mass thus the 
range of doses used may be wide. Seriously ill neonates are often fluid restricted, limiting 
the volume of medications that can be administered (Glass and Haywood, 2006).The skill 
and judgement of physicians and pharmacists are critical in ensuring appropriate drug, 
dosage form and dosing regimen.  
2.1.2 Improvements in regulations 
 
The Regulation of the European Parliament and of the council on medicinal product for 
paediatric use, which came into force in January 2007, obliges the pharmaceutical 
industry to undertake clinical trials also in the paediatric population (Regulation (EC) No 
1901/2006).  The Paediatric Regulation also requires marketing authorisation holders to 
submit to the competent authors all paediatric studies completed by the date of entry into 
force of the legislation.  
 
It is stated in the Regulation: “This Regulation aims to facilitate the development and 
accessibility of medicinal products for use in the paediatric population, to ensure that 
medicinal products used to treat the paediatric population are subject to ethical research 
of high quality and are appropriately authorised for use in the paediatric population, and to 
improve the information available on the use of medicinal products in the various 
paediatric populations. These objectives should be achieved without subjecting the 
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paediatric population to unnecessary clinical trials and without delaying the authorisation 
of medicinal products for other age populations” (Regulation (EC) No 1901/2006). 
 
EMEA and the Paediatric Working Group (PEG), in consultation with paediatric learned 
societies, have drawn up a priority list of off-patent products for which studies are required 
in (EMEA/197972/2007). In that list, it is mentioned that one of the group of compounds 
for which studies are required are the calcium channel blockers which are used in the 
treatment of chronic hypertension in all paediatric age groups. 
 
In the United States of America (USA), a mandatory regulation that requires 
manufacturers to assess the safety and effectiveness of new drugs and biological 
products in paediatric patients came into force almost ten years earlier than in Europe, in 
the year 1998. Later, in 2002 the authority to require certain research into drugs used in 
paediatric patients was given to US Food and Drug Administration (FDA) (FDA/Pub L No. 
107–109, 2002). It was only in 2007, that the European Commission (EC), EMEA and 
FDA agreed to expand their current cooperative activities, particularly those in paediatrics. 
 
2.2 Prevalence of extemporaneous preparation use in paediatric patients 
 
Despite efforts to improve the availability of suitable licensed and manufactured medicine 
products for children, extemporaneously prepared products are still needed to ensure that 
accurate and effective doses and dosage forms are available to achieve optimal drug 
therapy for children. Extemporaneous preparation is one facet of unlicensed drug use and 
includes modifications to commercially manufactured products such as the preparation of 
suspension or powders from tablets or the preparation of a product from the individual raw 
materials. Instead, dividing solid forms, dissolving tablets in water or administering 
fractions of a liquid to children, which is done on the wards by nurses, is not 
extemporaneous preparation. The use of extemporaneously prepared products is one way 
that prescribers are able to overcome the problems associated with the lack of approved 
medicines for children (Giam and McLachan, 2008).  
 
Giam and McLachlan (2008) reviewed 20 published studies to identify the relative extent 
of extemporaneous product use reported in the paediatric population and the implications 
for pharmacy practice. On general medical/surgical wards, the frequency of 
extemporaneous or ‘special’ product use was reported to range from 2% to 26%. On 
neonatal wards, extemporaneously prepared products or ‘specials’ were dispensed in 5–
  
13
11% of the prescriptions. In the United Kingdom (UK) it was reported that of the 9.9% 
extemporaneous products prescribed, 4.6% had been prepared extemporaneously by the 
pharmacy with the remaining 5.3% being prepared by ‘specials’ manufacturers. The use 
of extemporaneous products and ‘specials’ was similar across all paediatric ages and 
conditions. Although the cost of manufactured ‘specials’ has been reported to be much 
higher than for pharmacy-prepared extemporaneous products, the ‘specials’ industry in 
the UK has been noted to be thriving. Extemporaneous products are used most frequently 
in countries such as Netherlands where pharmacy preparation services are readily 
available. It has been estimated that more than 40% of doses given in paediatric hospitals 
require compounding to prepare a suitable dosage form (Glass and Haywood, 2006).  
 
Methods of extemporaneous preparation vary in different European countries (Brion et al., 
2003). Liquids are predominantly (> 60% of doses) prepared in Denmark, England, 
Ireland, Norway and Sweden, capsules in Belgium, Croatia, France and Switzerland and 
powders in Finland, Italy and Scotland. The practice in Germany, Spain and Slovenia 
involves the preparation of a less well-defined combination of liquids, powders and 
capsules. The study of Brion et al. (2003) collected information from 16 European 
countries with Kuopio University Hospital being one of the participants. In the USA and 
Canada, practicing pharmacists answered the questionnaire by stating that the most 
common extemporaneously prepared dosage form was a liquid formulation and  the most 
common route of administration for drug products was oral and / or gastric or nasogastric 
tube delivery (Pai and Nahata, 2001).  
 
The same drug may well be prepared in several different dosage forms, reflecting the 
different traditions of extemporaneous preparation in the different countries (Brion et al., 
2003). Many different concentrations were prepared for each dosage form. It was noted 
that 15 of the top 20 oral liquid preparations, 15 of the top 20 capsules and 6 of the top 20 
powders prepared extemporaneously were marketed as suitable licensed paediatric 
formulations in other European countries, North America or Australia. Thus, a total of 60% 
of those most important extemporaneous products could have been available as licensed 
products if there had only been more convenient ways to locate and import those 
medicines. Licensing authorities need to cooperate to ensure consensus of data to allow 
licensing in all European countries. In addition, there should be free movement of licensed 
medicines between European countries and information on availability should be readily 
available. 
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2.3 Quality of extemporaneous preparations 
 
The European Pharmacopoeia (2007) is used as an official regulation for extemporaneous 
preparation. General instructions of the extemporaneous preparation are presented in 
Medicinal products for human and veterinary use: Good manufacturing practice (Eudralex, 
2007) and in PIC/S Guide to good practices for the preparation of medicinal products in 
healthcare establishments (Pharmaceutical Inspection Convention, 2008). Other relevant 
pharmacopeial formularies are British Pharmacopoeia (BP), United States Pharmacopeia 
(USP), Australian Pharmacopoeia Formulae (APF) and Martindale (Glass and Haywood, 
2006). Suitable sources for finding stability-indicating formula include Allen’s compounded 
formulations, Nahata and Hipple’s Pediatric drug formulations and Trissel’s Stability of 
compounded formulations. 
 
However, extemporaneous preparation presents a range of challenging issues of concern 
when compared to off-label use of registered products or unlicensed use of commercially 
manufactured products and it is important to be aware of those potential problems (Table 
1) (Giam and McLachlan, 2008). There are no appropriate and comprehensive published 
standards for the process of extemporaneous preparation (Brion et al., 2003; Giam and 
McLachlan, 2008). To ensure product quality, harmonization of extemporaneous 
formulations and quality-control procedures are needed and collected data should be 
published as standards and uniformly implemented in all countries, and these should le ad 
to the creation of a monograph in a pharmacopoeia (Brion et al., 2003; Ghulam et al., 
2007; Giacoia et al., 2007b; Giam and McLachlan, 2008).  
 
In the USA and Canada, a questionnaire was sent to practicing pharmacists. It was noted  
that 103 drug formulations prescribed by paediatricians had no compounding and/or 
stability information available due to a lack of published stability-indicating analytical 
methods in peer reviewed journals (Pai and Nahata, 2001). Adequate stability data was 
found for 76 drug formulations. However, longer or better stability data were requested on 
109 formulations, such as captopril, hydralazine, spironolactone, ursodiol and nifedipine. 
Of the liquid dosage forms reviewed in the literature, the stability was considered to be 
unfavourable for only 6 of the 83 dosage forms (Glass and Haywood, 2006; Haywood and 
Glass, 2007). In an unpublished UK survey, it was noted that 54% of 112 paediatric 
extemporaneous formulations had inadequate data on stability (Brion et al., 2003).  
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Table 1. Problems and aims of concern in extemporaneously prepared drug products 
Problem  Reference 
Lack of published standards Brion et al., 2003 
Costello et al., 2007 
Ghulam et al., 2007 
Giacoia et al., 2007b 
Lack of access to various publications containing stability 
data on different drug formulations  
Pai and Nahata, 2001 
Lack of information about chemical, physical and 
microbiological stability data, short shelf-life 
Brion et al., 2003 
Giam and McLachlan, 2008 
Pai and Nahata, 2001 
Standing and Tuleu, 2005 
Lack of information about validation and reproducibility Costello et al., 2007 
Paediatric Formulary 
Committee, 2007 
Lack of proof of dose uniformity Costello et al., 2007 
Lack of adequate dosage form Costello et al., 2007 
Glass and Haywood, 2006 
Need to manipulate adult dosage form of the available tablet, 
capsule or injection, lack of pure drug substances 
Costello et al., 2007 
Cutting, crushing or dissolving of controlled-release tablets: 
release of the whole drug content at the same time that may 
lead to significant overdose 
Pagliaro, 2002 
Paediatric Formulary 
Committee, 2007 
Inability to swallow solid dosage forms Pai and Nahata, 2001 
Several different strengths prepared extemporaneously or as 
‘special’ products, 10-fold difference in available strengths 
Standing and Tuleu, 2005 
Alternative routes of administration for commercial products: 
e.g. oral liquids rectally, eye drops in the ear or injectable 
solution orally leading to irritability and altered kinetics of 
absorption and bioavailability 
Costello et al., 2007 
Glass and Haywood, 2006 
Dilution of commercial formulations leading to dilution of co-
solvents thus leading to the precipitation of the drug 
Glass and Haywood, 2006 
Microbiological contamination in multidose extemporaneous 
preparations with insufficient preservation leading to potential 
risks, especially in the premature and newborn  
Ghulam et al., 2007 
Variability in overall compounding practices and training Treadway et al., 2007 
Concern about ingredient compatibility  Giam and McLachlan, 2008 
Concern about compatibility between manipulated solid 
dosage forms and food/beverages 
Standing and Tuleu, 2005 
Taste of the drug or the preparation itself Standing and Tuleu, 2005 
Inaccuracy of dosing (dose uniformity and reproducibility) Paediatric Formulary 
Committee, 2007 
Standing and Tuleu, 2005 
Concern about bioavailability and efficacy Giam and McLachlan, 2008  
Paediatric Formulary 
Committee, 2007 
Standing and Tuleu, 2005 
Concern about safety Giam and McLachlan, 2008 
Difficulty in monitoring adverse reactions  Giam and McLachlan, 2008 
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In the future, it is presented that there will be a continuing requirement for 
extemporaneous preparation by pharmacists (Giam and McLachlan, 2008). An 
accreditation process has been implemented in the USA and is under discussion in 
Australia (Treadway et al., 2007). Pharmacists need to be provided with information about 
the stability, formulation and compatibility and equipped with the skills to produce 
effective, safe and stable preparations (Allen, 2006; Treadway et al., 2007). In the 
meantime, due to a general lack of information and peer-reviewed research in this field, a 
product should be dispensed extemporaneously only when no product with a marketing 
authorisation is available and if there are no alternatives (Brion et al., 2003; Paediatric 
Formulary Committee, 2007).  
2.3.1 Stability of extemporaneous formulations 
 
Stability refers to the chemical and physical integrity of the dosage unit and, when 
appropriate, the ability of the dosage unit to maintain protection against microbiological 
contamination (USP Pharmacists’ Pharmacopeia, 2008). The shelf life of a 
pharmaceutical product is the period during which, if stored correctly, it is expected to 
retain within specified limits, and throughout its period of storage and use, the same 
properties and characteristics that it possessed at the time of preparation (Barnes, 2007, 
Jew et al., 2003). Extemporaneous preparations are often given arbitrary shelf-lives or 
shelf-lives based on published information (Costello et al., 2007). It is important to ensure 
that an extemporaneous formulation packaged in a specific container will remain within its 
physical, chemical and microbiological specifications during storage for a specified time 
(Florence and Attwood, 2006). 
 
A short expiry period may be inconvenient for patients. The main causes for limited 
stability are: 1) loss of drug (by degradation), 2) loss of vehicle (by evaporation), 3) loss of 
uniformity (by caking of a suspension), 4) change of organoleptic characteristics 
(appearance), 5) change of bioavailability, 6) appearance of a degradation product that is 
irritant or toxic (Costello et al., 2007).  
2.3.1.1 Chemical stability 
 
Each active ingredient has to retain its chemical integrity and labelled potency within the 
specified limits (Allen, 2002). The limits of shelf life vary somewhat between different 
references. Usually the shelf life can be assumed to be the time taken for the 
concentration of the drug to be reduced to 95% of its value when originally prepared 
  
17
(Florence and Attwood, 2006). On the other hand, a reduction of content down to 90% of 
theoretical value (with possible 95% confidence bounds) is generally regarded as the 
maximum reduction acceptable (Barnes, 2007). Thus the limit of ≥ 90% of the initial 
concentration is also used (Glass and Haywood, 2006). 
 
Chemical degradation reactions can be sub-divided into hydrolysis, oxidation, 
isomerisation, polymerisation, and photochemical decomposition (Florence and Attwood, 
2006). Should these occur, then there will be a loss of potency of the drug, often 
accompanied by changes in the appearance of the product (e.g. discoloration, formation 
of a precipitate).  
 
Primary photochemical reaction occurs when the wavelength of the incident light is within 
the wavelength range of absorption of the drug, so that the drug molecule itself absorbs 
radiation and becomes degraded (photolysis) (Barnes, 2007; Florence and Attwood, 
2006). Photodegradation may also occur as a consequence of absorption of radiation by 
excipients which transfer the absorbed energy to the drug (Florence and Attwood, 2006). 
The degradation of photolabile drugs depends on both the intensity and spectral 
distribution of the light source (Thoma, 1996). Different numbers and structures of 
photodegradation products can be obtained by irradiating the drug in the solid state or in 
solution. 
 
In contrast to drug solutions, photodegradation in the solid state only takes place at the 
surface (Figure 1) (Thoma, 1996). The rate of decomposition is influenced by the size and 
surface of particles, the colour and crystalline structure, and layer thickness and 
excipients. The smaller the particle size, the greater the reactivity of the product (Allen, 
2002). Coating tablets with a polymer film containing ultraviolet absorbers is one method 
to achieve protection from light (Florence and Attwood, 2006). The layer thickness of the 
coloured and pigmented coating correlates strongly with the photoprotective effect 
(Thoma, 1996). Some light protecting pigments, e.g. titanium dioxide and iron oxide, can 
be added to the coatings. Iron oxide in particular has been demonstrated to possess a 
strong protection capacity with potent absorption of wavelengths below 400 nm. If the 
coating of the tablet is crushed, which is the case in extemporaneous preparation process, 
the photoprotection has to be assured with tinted packing materials. For example, 
coloured light-resistant containers and storage in the dark protects from photoinduced 
decomposition (Florence and Attwood, 2006). 
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Suspension formulations are often more stable than a formulation of the same drug in a 
solution because much of the drug is protected within the insoluble particles (Barnes, 
2007). The solubility of the suspended drug changes with increase in temperature 
(Florence and Attwood, 2006). In suspensions, the concentration of solute drug usually 
remains constant because, as the decomposition reaction proceeds, more of the drug 
dissolves to keep the solution saturated.  
 
 
Figure 1. Photoinstability of nifedipine crystals (≤ 5µm) compared with nifedipine solution: 
-●- nifedipine crystals; -○- nifedipine solution, c0 = 3 mg/50 ml (adapted from Thoma, 
1996). About 20 % of the crystalline nifedipine has become decomposed within 40 
minutes, subsequently, further degradation does not occur during the next 40 minutes 
whereas a solution decomposes completely during the period.  
 
 
The determination of the shelf life of a formulated product needs to be performed on the 
actual product at a realistic storage temperature, normally at room temperature or in a 
refrigerator (Barnes, 2007). An accurate, specific, reproducible and stability-indicating 
analytical method, e.g. high-performance liquid chromatographic technique should be 
used (Nahata, 1999). A specific protocol for testing the photostability of new drugs and 
products is described in the ICH Guideline (ICH Harmonised Tripartite Guideline, 1998). 
2.3.1.2 Physical stability 
 
Physical stability means that the original physical properties, including appearance, 
palatability, uniformity, dissolution and suspendability, have been retained (Allen, 2002). 
Physical instability can either spoil the product’s appearance or reduce its effectiveness 
(Barnes, 2007). Potential problems may also be loss of drug due to sorption, evaporation 
or contamination of the product by extractives.  
 
Physical changes indicating instability in capsules could include changes in the physical 
appearance or consistency, including softening or hardening of the shell, or discoloration, 
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expansion or distortion of the gelatine capsule (Allen, 2002). Caking instead of free 
flowing may occur in powders. Furthermore, discoloration and release of pressure upon 
opening may possibly occur. 
 
Physical instability in dispersed systems such as suspensions is expressed as caking of 
sediment or particle growth (Barnes, 2007). It is recommended that the rate of 
sedimentation of solids undissolved in the preparation should not be too rapid (Costello et 
al., 2007). The particles that settle onto the bottom of the container must not form a hard 
cake, but should be readily dispersed into a uniform mixture when shaken. Redispersion 
of the preparation can be affected by the changes in viscosity. Precipitation of active 
ingredients or excipients can lead to erratic dosing or affect the quality of the preparation. 
Hurtado and Moffett (2007) reported one case of a neonate readmitted with an arrhythmia 
because an amiodarone suspension had been incorrectly compounded and the solids had 
settled into a hard mass at the bottom of the container.  
 
The particle size of the active ingredient in suspension can affect the uniformity of content 
since large particles will settle faster than their smaller counterparts (Costello et al., 2007). 
Particle size may increase as a result of sedimentation, aggregation or crystallization, 
which can occur due to Ostwald ripening, changes in storage temperature or the 
appearance of polymorphic forms. Thus, the suspension needs to be observed for 
uniformity, settling, caking, crystal growth and difficulty in resuspending, as well as odour 
and loss of volume (Allen, 2002). Viscosity should also be monitored as changes can 
affect the redispersion and pourability of the product, and impair dosing. In practice, 
adequate testing includes the ease of redispersion in parallel with the dose uniformity 
(Costello et al., 2007).  
2.3.1.3 Microbiological stability 
 
Microbial quality or resistance to microbial growth has to be retained according to the 
specified requirements (Allen, 2002; European Pharmacopoeia 6.1, 2007). Products 
containing sufficient water to permit bacteria or fungi growth are vulnerable to spoilage 
(Hodges, 2007). Only spore-formers survive well in dry conditions. Most bacteria have an 
optimum pH for growth near neutrality, whilst most fungi favour slightly acidic conditions. 
 
Products contaminated with pathogenic organisms may be an infection hazard (Hodges, 
2007). The occurrence of microbiological growth in aqueous medicines can affect the 
organoleptic characteristics of the product, producing turbidity, bad odour or taste 
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(Costello et al., 2007; Ghulam et al, 2007). Deterioration of the product due to bacterial or 
mould growth can either render the product unacceptable, harmful or toxic to the patient 
(Barnes, 2007; Costello et al., 2007; Hodges, 2007). The presence of micro-organisms 
and their metabolites can even impair the chemical or physical stability and the drug 
solubility by affecting the pH (Costello et al., 2007; Hodges, 2007). For example, air 
contamination of a cellulose syrup mixture or unhygienic use of the product can also lead 
to microbiological contamination (Costello et al., 2007; Nahata et al., 2003).  
 
There are pharmacopoeial requirements for microbiological quality of oral preparations, 
i.e. not more than 103 bacteria and not more than 102 fungi per gram or per millilitre, and 
the absence of Escherichia coli (European Pharmacopoeia 6.1, 2007). Hygienic 
manufacture, sterilization and suitable preservatives are used to prevent the presence or 
growth of microorganisms in the product (Billany, 2007). The factors impacting on the 
hygienic manufacture of medicines are air, building, equipment, work surfaces, raw 
materials, both ingredient and cleaning water, formulation and personnel (Hodges, 2007). 
Health, hygiene, clothing and training of the personnel may all have an impact on product 
contamination. 
 
2.4 Oral dosage forms for neonates and infants  
 
The ideal oral drug preparation should be effective, well tolerated, stable, affordable, and 
have good palatability, e.g. acceptable taste, after-taste and smell (Pawar and Kumar, 
2002). This is important since the taste buds and olfactory receptors are well developed in 
children and therefore flavouring and sweetening are needed for many drugs with an 
unpleasant taste (e.g. chloral hydrate), smell (e.g. phenytoin) or texture (e.g. liquid 
antacids) (Allen, 2002). The age-related differences in the taste and smell has to be taken 
into account (Pawar and Kumar, 2002). Drugs with an acidic taste can be blended with 
citrus fruit flavours (Allen, 2002). Salty, sweet and sour tastes can be used to mask the 
bitter taste of high molecular organic compounds. The addition of a slightly salty taste may 
decrease sourness and increase sweetness. In patients with nasogastric tubes, the taste 
of the product is not relevant (Pawar and Kumar, 2002).  
 
If the formulation is unsuitable administration of medications to paediatric patients can be 
stressful, traumatic and sub-therapeutic (Costello et al., 2007).  Oral liquid dosage forms 
should be administered to infants when they are in the same position as for breast- or 
bottle feeding to prevent aspiration of the drug and to prevent the drug from running out of 
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the infant’s mouth (Pagliaro, 2002). In the newborn, oral liquids need to be dispensed via 
a plastic nipple to take advantage of their strong suckling reflex. If the infant refuses the 
nipple, the drug can be delivered via a plastic oral drug syringe. Small amounts of the 
drug should be placed between the infant’s cheek and gum toward the back of the mouth. 
The infant’s throat can be gently stroked outside in a downward motion to facilitate 
swallowing.  
 
For many infant patients, drugs have to be administered through nasogastric feeding 
tubes (Pagliaro, 2002). One report stated that nurses considered the occlusion of 
nasogastric tubes to be a significant problem in using oral powders (Hepojoki, 2008). The 
type of the feeding tube (material, size of the bore, nasogastric or gastrostomy), 
placement (stomach, duodenum, jejunum), enteral nutrition and feeding schedule can 
affect drug administration, absorption and drug-nutrient interactions (Pagliaro, 2002). 
Feeding tubes made of polyurethane have a lower incidence of clogging compared to 
other materials. Tube occlusion can be prevented also with flushing before and after the 
administration of drugs and enteral feedings, and also between different drugs (Pagliaro, 
2002; Paediatric Formulary Committee, 2007). In neonates sterile water must be used to 
rinse the medicine down via a nasogastric tube.  
 
Liquid oral medicines have an advantage compared to solid dosage forms (Costello et al., 
2007). An ideal delivery system is accurate, suits all the age groups, and has a minimal 
dosage frequency and a good palatability. It should also contain only few non-toxic 
excipients and be easy to administer. Finally, it has to be a stable formulation which is 
commercially available. 
2.4.1 Active ingredient 
 
The active ingredient of the extemporaneous formulation may be: 1) drug substance of 
pharmacopoeial standard, 2) from manipulated licensed formulation, including also 
excipients or, 3) though not recommended, a chemical without official standards which 
may have been purchased from a variety of sources and submitted to varying procedures 
to establish the quality. These chemicals are often not sold as ingredients for the 
preparation of medicines (Brion et al., 2003). 
 
Ideally, extemporaneous products are prepared from pure drug substances, but more 
frequently, because of the easier availability, commercial dosage forms intended for adults 
are manipulated by crushing the tablet or opening the capsule and using the contents 
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(Brion et al., 2003; Costello et al., 2007). The resulting powder may be dissolved or 
suspended with various excipients to produce an oral liquid medicine, or it may be 
redistributed in smaller strength capsules or powder papers, usually after dilution with 
lactose or some other inactive ingredient. It is important that the uniformity of dose 
distribution is checked according to appropriate pharmacopeial monographs (Costello et 
al., 2007; European Pharmacopoeia 6.1, 2007). 
 
Active ingredient of this work, nifedipine is sensitive to light (European Pharmacopoeia 
6.1, 2007; Thoma, 1996). Although UV-light in the energy-rich short-wavelength region is 
very often the cause of the degradation of drugs, a distinct spectral region of visible light 
seems to be responsible for the main photolysis of nifedipine (Figure 2). The graph shows 
that nifedipine solution is stable down to a wavelength of 475 nm, and that photolysis 
begins at 450 nm and increases considerably up to 400 nm. Nifedipine is converted to a 
pharmacologically inactive nitrosophenylpyridine derivative when exposed to daylight and 
artificial light of certain wavelengths, and to a nitrophenylpyridine derivative when exposed 
to ultraviolet light (Figure 3). 
 
 
 
 
 
 
Figure 2. Influence of the wavelength of the irradiation light on the photostability of 
nifedipine;  (-●-) dependence of the residual concentration on the wavelength of xenon 
radiation (left ordinate); (–) long wavelength section of the nifedipine adsorption spectrum 
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Figure 3. Photochemical decomposition products of nifedipine: (1) nitrophenylpyridine 
derivative, (2) nitrosophenylpyridine derivative; (3) azoxy derivative (adapted from Thoma, 
1996)  
 
2.4.2 Excipients 
 
Excipients, inert ingredients, are added to increase the bulk, add desirable colour, mask 
the unpleasant taste and smell and facilitate a uniform mixture of the active ingredient in 
the final preparation (Pawar and Kumar, 2002). Very small amounts of active ingredients 
require a carrier to ensure their uniform distribution in the dispensed product, and to 
guarantee an accurate dose.  
 
Bulk fillers contribute to the product’s uniformity, stability, flow characteristics and 
compressibility (Pawar and Kumar, 2002). Lactose is widely used as a filler or diluent in 
tablets and capsules, and to a more limited extent in infant formulas (Rowe et al., 2007). 
Lactose, a disaccharide of glucose and galactose is, however, absorbed after hydrolysis 
by the intestinal enzyme, lactase (Pawar and Kumar, 2002). Microcrystalline cellulose, 
which is derived from purified wood cellulose by acid hydrolysis is primarily used as a 
binder and diluent in oral tablet and capsule formulations (Pawar and Kumar, 2002; Rowe 
et al., 2007). Cellulose causes no systemic adverse effects, because it is not absorbed by 
1 
2 
3 
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humans. Colloidal cellulose is used as a suspending agent for active ingredients in liquid 
preparations. Hypromellose, hydroxypropylmethylcellulose, is a purified form of cellulose, 
cotton lints or wood pulp. It is used both as tablet binder, in film-coating, as matrix in 
sustained-release tablet formulations and as a suspending and thickening agent in liquid 
formulations (Rowe et al., 2007). Hypromellose is regarded as a non-toxic and non-irritant 
material, although excessive oral consumption may have a laxative effect. Purified water 
is the most commonly used solvent in liquid preparations (Pawar and Kumar, 2002; Rowe 
et al., 2007). However, water may serve as a culture medium for bacteria and fungi 
(European Pharmacopoeia 6.1, 2007). Purified water is prepared by distillation, ion 
exchange, reverse osmosis or by some other suitable method.  
 
Excipients have been considered to be almost inert in adults; however, rare adverse 
effects, particularly in children, have been reported (Table 2). They may lead to life 
threatening toxicity in paediatric patients when multiple doses of medications with the 
same preservative are employed (e.g. benzyl alcohol and benzoic acid) (Glass and 
Haywood, 2006). Dose-related adverse effects of excipients are of particular concern in 
the preterm newborn, low-birthweight neonates and infants, this being attributable to the 
immaturity of hepatic and renal function (Costello et al., 2007). 
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Table 2. Reported adverse effects caused by excipients especially in children 
Excipient Adverse reaction Reference 
Bulk fillers: 
Lactose Diarrhoea, malabsorption, vomiting, flatulence (in patients 
with lactose-intolerance) 
Jaundice, hypoglycaemia, CNS symptoms, cataracts (in 
patients with galactosemia)  
Kumar et al., 1996 
Sweeteners and flavouring agents: 
Aspartame Headache, grand mal seizures, memory loss, 
gastrointestinal symptoms, dermatological symptoms 
(large quantities) 
Potentially toxic metabolites methanol, aspartic acid and 
phenylalanine 
Phenylalanine is harmful in patients with phenylketonuria 
Aspartic acid is neurotoxic and epileptogenic 
American Academy 
of Pediatrics, 1997 
Pawar and Kumar, 
2002 
Rowe et al., 2007 
Fructose Hypoglycemia (in patients with fructose intolerance) Kumar et al., 1996 
Menthol Hypersensitivity reactions, systemic allergic reactions Kumar et al., 1993 
Peppermint oil Atrial fibrillation, muscle pain, cooling or burning 
sensations 
Kumar et al., 1993 
Saccharin 
Saccharin 
sodium 
Irritability, hypertonia, insomnia, opisthotonus and 
strabismus, cross-sensitivity with sulfonamides 
Approved for children >3 years 
Costello et al., 2007 
Pawar and Kumar, 
2002 
Sodium 
cyclamate 
Incidence of bladder cancer increased in rats 
Use is restricted in many countries 
Costello et al., 2007 
Sorbitol, 
mannitol, 
xylitol 
Large amounts: osmotic diarrhoea  Pawar and Kumar, 
2002 
Sucrose Tooth decay 
Cariogenicity, increased degradation of active drug, 
allergic reactions (very rare) 
Costello et al., 2007 
Kumar et al., 1996 
Colouring agents: 
Azo dyes  Anaphylactic reactions, angioedema, asthma, urticaria, 
hyperkinesis, cross-sensitivity with acetylsalicylic acid, 
sodium benzoate and indomethacin (tartrazine FD&C 
yellow5 = E102, sunset yellow FD&C 6 = E110) 
Pawar and Kumar, 
2002 
Quinoline dyes Contact dermatitis Pawar and Kumar, 
2002 
Triphenyl-
methane dyes 
Bronchoconstriction (brilliant blue FCF: FD&C blue1 = 
E133), erythema multiforme-like skin rash (fast green 
FCF: FD&C green3), anaphylaxis, angioedema 
(fluorescein: FD&C yellow7) 
Pawar and Kumar, 
2002 
Xanthine dyes Photosensitizer (eosin: FD&C red22), carcinogenicity 
(erythrosine: FD&C 3 = E127) 
Pawar and Kumar, 
2002 
Preservatives and antibacterial agents: 
Benzalkonium 
chloride 
Dose-related bronchoconstriction, cough, burning 
sensation, occasionally facial flushing, pruritus 
American Academy 
of Pediatrics, 1997 
Costello et al., 2007 
Benzoic acids 
and benzoates 
Displacement of bile from albumin binding sites in 
premature neonates, ‘gasping syndrome’ 
Costello et al., 2007 
Kumar et al., 1993 
Benzyl alcohol A number of neonatal deaths and severe respiratory and 
metabolic complications (32–105 mg/kg/d), bronchitis, 
haemoptysis, hypersensitivity reactions (rare) 
American Academy 
of Pediatrics, 1997 
Boric acid Is not used internally owing to its toxicity: death from 
ingestion of <5g in young children  
Rowe et al., 2007 
Parabens Skin sensitization and cross-sensitization with each other 
Concern has been expressed over the use of 
methylparaben in infants’ parenteral products because 
bilirubin binding may be affected, which is potentially 
hazardous in hyperbilirubinemic neonates 
Costello et al., 2007 
Kumar et al., 1993 
Rowe et al., 2007 
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The WHO has set an estimated total acceptable daily 
intake for methyl-, ethyl-, and propylparabens at no more 
than 10 mg/kg 
Sodium 
benzoate 
Nonimmunological contact urticaria, anaphylaxis 
It has been recommended that sodium benzoate injection 
should not be used in neonates 
Rowe et al., 2007 
Sodium borate Damaged skin, severe toxicity (vomiting, diarrhoea, 
erythema, CNS depression, kidney damage) 
Lethal oral intake 5g in children 
Rowe et al., 2007 
Thiomersal Hypersensitivity (at 0.1% concentration in children) Rowe et al., 2007 
Surfactants and solubilising agents: 
Ethanol Accumulation of acetaldehyde  
In the USA, the maximum quantity of alcohol included in 
OTC medicines is: 10% v/v for use by individuals of 12 
years of age and older, 5% v/v for children aged 6–12 
years of age, and 0.5% v/v for children under 6 years of 
age  
In Europe there are no limits set 
Costello et al., 2007 
Pawar and Kumar, 
2002 Rowe et al., 
2007 
 
Ethylene 
glycol 
Renal failure (in 1937, children treated with 
sulphanilamide elixir developed renal failure traceable to 
the ethylene glycol which had been used as a solvent) 
The WHO has set an estimated acceptable daily intake of 
polyethylene glycols at no more than 10 mg/kg 
Pawar and Kumar, 
2002 
Rowe et al., 2007 
Glycerol >40% in volume: mucositis, diarrhoea, electrolyte 
disturbances 
Pawar and Kumar, 
2002 
Polysorbate Hypersensitivity 
Serious adverse effects (E-Ferol syndrome: 
thrombocytopenia, renal dysfunction, hepatomegaly, 
cholestasis, ascites, hypotension and metabolic acidosis, 
including some deaths, in low-birthweight infants 
The WHO has set an estimated acceptable daily intake at 
no more than 25 mg/kg 
Costello et al., 2007 
Rowe et al., 2007 
Propylene 
glycol 
One-third as intoxicating as ethanol 
Effects on central nervous system 
Ototoxicity, cardiac arrhythmias, seizures, osmotic laxative 
effects, contact dermatitis lactic acidosis (especially in 
neonates and children <4 years of age) 
Acceptable daily intake up to 25 mg/kg  
Not recommended for children <4 years (limited alcohol 
dehydrogenase) 
Half-life 17h in neonates (5h in adults) 
American Academy 
of Pediatrics, 1997 
Costello et al., 2007 
Rowe et al., 2007 
 
Miscellaneous groups, e.g. antioxidants, lubricants, etc: 
Liquid paraffin Lipoid pneumonia caused by aspiration or use of 
ophthalmic preparations 
Should not be used in very young children 
Rowe et al., 2007 
Potassium 
metabisulphite 
Bronchospasm, anaphylaxis (especially in those with a 
history of asthma or atopic allergy) 
Rowe et al., 2007 
Povidone Anaphylactic reaction Costello et al., 2007 
Sulphites Wheezing, dyspnoea, chest tightness (in patients with 
known reactive airway disease) 
Anaphylaxis, hives, itching 
 
American Academy 
on Pediatrics, 1997 
Pagliaro, 2002 
Thymol Respiratory arrest, nasal congestion edema (reported in 
newborn) 
Not for children under 5 years 
Rowe et al., 2007 
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2.4.3 Oral solid dosage forms 
 
The main groups of oral solid dosage forms are: oral powders, granules, capsules, gastro-
resistant capsules, prolonged-release capsules and tablets (National Agency for 
Medicines, 2008b). In this review, oral powders and capsules and in addition, splitting of 
tablets will be discussed. 
2.4.3.1 Oral powders 
 
Oral powders are preparations consisting of solid, loose, dry particles of varying degrees 
of fineness (European Pharmacopoeia 6.1, 2007). They contain one or more active 
substances, with or without excipients. Single-dose oral powders are individually weighed 
powders packed individually in folded powder papers (Allen, 2002; Brion et al., 2003; 
European Pharmacopoeia 6.1, 2007). Since powders are dry, they generally represent a 
stable dosage form as long as they are protected from moisture and heat (Allen 2002; 
Brion et al., 2003). Powders have a large surface area that is exposed to atmospheric 
conditions (Allen, 2002). Small particles are more reactive and can absorb larger 
quantities of gases, such as carbon dioxide.  
 
Single-dose oral powders are more time consuming to prepare than capsules or oral 
liquids. Different strengths may be required to medicate children of different ages. The 
taste or caustic nature of the active drug may limit their use (Allen, 2002; Brion et al., 
2003). Usually the powders are administered in water, milk, some other beverage or food 
if any incompatibilities are not present (Allen, 2002). Powders should never be ingested 
without first moistening them because of the possible aspiration or choking hazard 
(Pagliaro, 2002). 
 
The first step in the bulk powder preparation is to ensure that all the components of the 
mixture are in the same particle size range (Allen, 2002). Size reduction or comminution of 
a tablet is carried out by a process of crack propagation, whereby localized stresses 
produce strains in the particles which are large enough to cause bond rupture (Staniforth 
and Aulton, 2007). In small scale preparation, comminution involves mainly manual 
methods, e.g. trituration, levigation and pulverization by hand (Allen, 2002). Gummy-type 
materials are best comminuted using pulverization, insoluble materials for suspension by 
levigation and hard fracturable powders by trituration. Once pulverized by trituration, the 
powder should be levigated with a levigating agent to form a smooth paste (Jew et al., 
2003).  
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Whenever a product contains more than one component, a mixing or blending stage is 
required in the manufacturing process to ensure an even distribution of the active 
components (Twitchell, 2007). When mixing a small amount of a potent drug in a powder 
mix, the degree of mixing must be of a high order to ensure a consistent dose. The lower 
the proportion of active component present in the mixture, the more difficult it is to achieve 
an acceptably low deviation in the active content. Secondly, the more particles that are 
present in a unit dose, the lower the probable variation in content. Therefore, by 
decreasing the particle size, the variation may be reduced but on the other hand, 
increased cohesion and adhesion with smaller particles can lead to particle aggregation.  
 
Particles larger than 250 µm are usually relatively free flowing but as the size falls below 
100 µm, powders become cohesive and flow problems are likely to occur (Staniforth and 
Aulton, 2007b). If the particle size is less than 10 µm, powders are usually extremely 
cohesive and resist flow under gravity, except possibly as large agglomerates. A powder 
that is too fluffy can be compacted slightly by the addition of a few drops of alcohol, water, 
or liquid paraffin (Twitchell, 2007). Magnesium stearate, less than 1% of the total weight 
enhances the lubrication and flow characteristics. Electrostatic forces can be neutralized 
with sodium lauryl sulphate, up to 1%. It in turn may reduce the ease of mixing. On the 
other hand, a sufficiently small powder may become adsorbed onto ‘active sites’ on the 
surface of a larger ‘carrier’ particle. However, it is possible to estimate by calculation the 
particle size required to achieve a formulation with the desired specifications. 
 
Pharmaceutical mixing is a process called geometric dilution (Allen, 2002). It is started 
with the ingredient in the smallest quantity, and then additional ingredients are added in 
order of quantity required by approximately “doubling” the portion being mixed with each 
addition. Mixing can be done in a mortar with a pestle. Mortars need to be nonporous so 
that no drug substance remains in the pores to decrease the dose or to contaminate the 
next product to be prepared. When handling hazardous drugs mixing powders in a plastic 
bag using a spatula can lessen the amount of powder suspended in the air around the 
preparation area.  
 
Pharmaceutical mixes are likely to be partly ordered (particles are not independent of 
each other) and partly random, the extent of each amount depending on the component 
properties (Twitchell, 2007). Components of neutral mixtures like powders have no 
tendency to mix or segregate spontaneously once work has been done to mix them. 
However, powders of different particle size may become segregated during mixing or 
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storing and shipping (Allen, 2002). Segregation will cause an increase in content variation 
(Twitchell, 2007). Typically, powder mixes contain particles that differ in size, shape and 
density and thus will tend to behave differently. More dense large particles tend to settle 
more rapidly than small particles (Allen, 2002; Twitchell, 2007). However, smaller particles 
tend to fall through the voids between larger particles and thus move to the bottom of the 
mass (percolation segregation) (Twitchell, 2007). Larger particles will tend to have greater 
kinetic energy imparted to them during mixing and therefore move greater distances than 
smaller particles (trajectory segregation).  These effects together lead to the fact that there 
is a tendency to find larger particles at the edge of the powder heap when they are poured 
out of the container. The use of excipients which have a density similar to the active 
component is one approach to minimize segregation.  
2.4.3.2 Hard gelatine capsules 
 
Hard capsules have shells consisting of two prefabricated, cylindrical sections, each of 
which has one rounded, closed and one open end (European Pharmacopoeia 6.1, 2007). 
The active substances are filled into one of the sections that is then closed by slipping the 
other section over it. Normally this dosage form is intended to be swallowed whole, but for 
some purposes such as administering for infants, the capsules are opened before 
administration and the contents gently mixed with a small amount of suitable liquid or soft 
food (Allen, 2002; Brion et al.; 2003, Pagliaro, 2002). 
 
The primary ingredients of hard gelatine capsule shells are gelatine, sugar and water, but 
they may also contain a dye and/or an opacifying agent and about 0.15% sulphur dioxide 
to prevent decomposition (Allen, 2002). Hard gelatine capsules normally contain about 
10–15% moisture, though gelatine can absorb up to 10 times its weight in water (Allen, 
2002, Jones 2007).  
 
The capsule size selected should be slightly larger than is needed to hold the drug 
substance, because excipients are needed to produce a full capsule (Allen, 2002). For 
children capsules number 1–5, that is capacities of 0.50–0.12 ml, are normally used. 
Manually operated capsule filling devices are suitable for small scale production (Allen, 
2002; Brion et al., 2003).  
 
The excipients in capsule formulation can have a significant effect on the rate of 
dissolution of poorly soluble and hydrophobic drugs (Ashford, 2007). Hydrophilic diluents 
like lactose often increase the rate of penetration of gastrointestinal fluids into the contents 
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of the capsule and thus promote the dispersion and dissolution of the drug. Increase in 
packing density of the encapsulated mass is believed to decrease liquid permeability and 
also the dissolution rate whereas the use of a surfactant may facilitate liquid penetration. 
2.4.3.3 Splitting of tablets 
 
Instead of extemporaneous preparation, tablets are sometimes cut into smaller segments 
in the pharmacy or on the ward to obtain appropriately-sized dosage units for children 
(Brion et al., 2003). These segments are defined as tablets cut into halves, quarters or 
smaller pieces. They are often crushed before administration in liquid or with food. The 
extent of ward-based segmenting of tablets is unknown, but it is believed to be extensive 
and might well occur if pharmacies have neither the time nor the information to provide 
other possibilities (Brion et al., 2003; Hepojoki, 2008) 
 
Unequal breaking of tablets may result in dose variability (Teng et al., 2002; van Santen et 
al., 2002). Some tablets cannot be easily divided in half because of their size, a shallow 
score line, or thickness (van Santen et al., 2002; Sedrati et al., 1994). Even when 
commercial tablet cutters are used, the accuracy of splitting may be variable (Marriott and 
Nation, 2002; Sedrati et al., 1994; Teng et al., 2002). Uniformity of the drug content in 
different parts of the tablet may be unknown because content uniformity is tested only with 
undivided tablets. Splitting of tablets may also lead to loss of mass, due to powdering and 
fragmentation of the score line (Costello et al., 2007; van Santen et al., 2002; Teng et al., 
2002). In one study, over 40% of manually split tablet portions (n = 1752) deviated from 
ideal weight by more than 10% and over 10% deviated by more than 20% (McDevitt et al., 
1998). Greater than 15% variation of the intended mean half-tablet weight was found in 
certain products when they were split in half with a commercial splitter (Sedrati et al., 
1994). Similar results have been found also by other investigators; the weight of a split 
tablet can range even from 50% to 150% of the actual half-tablet weight (Costello et al., 
2007; van Santen et al., 2002). Teng et al (2002) found that of the 11 split tablet products 
(10 tablets for each product) evaluated, only three products passed the uniformity of 
dosage units test of the United States Pharmacopeia.  
 
Uneven breaking of tablets may lead to significant fluctuations in the administered dose 
(Marriott and Nation, 2002). This may be clinically significant for drugs, which have a 
narrow therapeutic range. If the half-life of drug is long or the therapeutic range is wide, 
dose fluctuations are less likely to be clinically significant. The degree of inaccuracy 
seems to be associated with tablet size, shape and type of score line. Oval 10-mm tablets 
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with deep scores on both sides were most accurate in manual splitting (McDevitt et al., 
1998). The tablet-splitting device was most accurate with larger (> 600 mg) tablets that 
were coated, and had an oblong shape and flat edges.   
 
The tablet dissolution rate and absorption characteristics of coated and controlled-release 
tablets may be affected when tablets are split (Marriott and Nation, 2002). Splitting may 
also expose a drug’s taste, which has been masked in the coated tablet. A controlled-
release tablet that has been split may produce overdose, which could lead to a number of 
adverse effects (Sam, 2002). Finally, enteric-coated tablets also should not be split. 
2.4.4 Oral suspension 
 
Main groups of oral liquid dosage forms are as follows: oral drops, oral liquids, oral 
solutions, oral suspensions, oral emulsions and syrups (National Agency for Medicines, 
2008b). In this review, only oral suspensions will be discussed. 
 
A pharmaceutical suspension is a coarse dispersion in which insoluble particles, generally 
greater than 1µm are dispersed in a liquid (usually aqueous) medium (Attwood, 2007). 
Oral liquids are comparatively quick to prepare and allow versatility in dosage (Brion et al., 
2003). For the extemporaneous preparation of suspensions on a small scale, the 
powdered drug can be mixed with the suspending agent and some of the vehicle using a 
mortar and pestle (Billany, 2007). The dosage can be measured from a single strength 
preparation by using an oral syringe (Brion et al., 2003). However, under these conditions 
it may be difficult to ensure palatability, as well as physical, chemical and microbiological 
stability. Preparations for oral administration should not include more than 103 bacteria 
and not more than 102 fungi per gram or per millilitre (European Pharmacopoeia, 6.1, 
2007). New guidelines on the standards required for the preparation of non-sterile liquids 
in healthcare establishments recommend using closed systems for processing and 
transferring to protect the product from contamination (Pharmaceutical Inspection 
Convention, 2008). 
 
It has been stated that an aqueous suspension is a useful dosage form for administering 
insoluble or poorly water-soluble drugs (Ashford, 2007). For poorly soluble drugs like 
nifedipine, dissolution is the limiting step in absorption (Costello et al, 2007). Based on 
Noyes-Whitney equation, it is known that if the dispersed drug in the suspension has a 
large surface area then this will enhance dissolution and hence absorption (Attwood, 
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2007). In contrast to powder-filled hard gelatine capsules, dissolution of all drug particles 
begins immediately on dilution of the suspension in gastrointestinal fluids (Ashford, 2007). 
 
Solutions and elixirs can be particularly irritating to the gastric mucosa and may be 
associated with adverse drug reactions like nausea and vomiting (Pagliaro, 2002). Gastric 
irritation and osmotic diarrhoea may result from administering drugs that increase the 
osmolality of the GI contents.   
2.4.4.1 Sedimentation and redispersion  
 
The product must remain sufficiently homogenous for at least the period between shaking 
the container and measuring the required amount (Billany, 2007; Marriott, 2007). In a 
suspension formulation where there is a dispersion of solids in a liquid of low viscosity, the 
components will tend to separate out and energy must be continuously supplied to keep 
the components adequately dispersed (Twitchell, 2007). The problems of the suspension 
include sedimentation, caking (close packing of the sedimented particles), flocculation and 
particle growth that occurs due to temperature fluctuations and these can all affect the 
solubility of the drug (Billany, 2007; Florence and Attwood, 2006). Adhesion of suspension 
particles to container walls has also been noted as a problem, particularly with low-dose 
drugs.  
 
There has to be a balance between attractive and repulsive forces (Attwood, 2007). The 
electrical repulsive forces between the particles allow the particles to slip past one another 
to form a close packed arrangement at the bottom of the container, with the small particles 
filling the voids between the larger particles. Instead, a flocculated suspension will form 
loosely bonded sediments (Attwood, 2007; Billany 2007). A flocculate is a cluster of 
particles that do not settle as individual particles but are held together in a loose open 
structure (Florence and Attwood, 2006). The supernatant clears rapidly, but because of 
the random arrangement of the particles in the flocks, the sediment is not closely packed. 
The rapid clearance of the supernatant in a flocculated system produces the risk of an 
inaccurate dose being administered (Billany, 2007; Florence and Attwood, 2006). On the 
other hand, in a completely deflocculated system the particles are not associated. 
Pressure on the individual particles can lead to close packing of the particles to such an 
extent that the particles become irreversibly bound together. Thus, a suspension needs to 
be partially flocculated to enable easy redispersion and also it should be viscosity 
controlled to minimise the sedimentation rate. 
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Cake formation, the most serious physical stability problem of suspensions, may occur 
due to the formation of bridges between the particles (Attwood, 2007; Billany, 2007; 
Florence and Attwood, 2006). This cannot be totally prevented by reduction of particle 
size or by increasing the viscosity of the continuous phase. Fine particles can fill the voids 
between the larger ones and form more closely packed sediment which may be difficult to 
redisperse (Attwood, 2007; Florence and Attwood, 2006). Flocculating agents can prevent 
caking whereas deflocculating agents increase the tendency to cake (Florence and 
Attwood, 2006). The zeta potential of the particles can be measured to determine whether 
one should add flocculating or deflocculating agents. Thickeners produce a viscous 
medium and thus prevent the movement of the particles and sedimentation becomes 
delayed. In practice, the ease of redispersion in parallel with the uniformity of dose need 
to be tested (Costello et al., 2007). 
 
For extemporaneous suspensions, it has been claimed that the ideal suspending agent 
should be readily dissolved or dispersed in water without resort to special techniques and 
should not influence the dissolution rate or absorption rate of the drug (Florence and 
Attwood, 2006). The hydrocolloids such as several non-Newtonian pseudoplastic cellulose 
derivatives used as suspending agents may produce a deflocculated system, particularly if 
used at low concentrations (Billany, 2007; Marriott, 2007). Hydrophilic colloids protect the 
solid hydrophobic particles with a multimolecular layer and thus impart a hydrophilic 
characteristic which promotes wetting. However, it is essential that the areas on each 
suspended particle remain free from absorbate, so that cross-linking can recur after the 
product is shared. 
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3 AIMS OF THE STUDY 
 
The aim of this licentiate study was to evaluate the pharmaceutical quality of hospital 
pharmacy-prepared extemporaneous oral nifedipine dosage forms and their feasibility for 
use as paediatric medications. 
 
Specific aims were: 
 
1. to determine the content uniformity of nifedipine in oral powders and capsules 
prepared from crushed tablets with different amounts of lactose monohydrate or 
microcrystalline cellulose,  
 
2. to determine the stability of nifedipine in oral powders for up to one year, 
 
3. to formulate an oral liquid dosage form of nifedipine from both commercially available 
tablets and pure drug powder with a hypromellose solution for small-scale production 
and to determine the content uniformity of the suspension, and 
 
4. to determine the short-term (1 month) chemical, microbiological and physical stability 
of an oral nifedipine suspension which was packaged in a capped unit-dose syringe. 
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4 MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Nifedipine 
 
The drug substance, nifedipine, was obtained either as the drug powder (Orion 
Corporation, Turku, Finland) or from crushed tablets (Adalat 10 mg retard, Bayer AG, 
Leverkusen, Germany). Nifedipine is practically insoluble in water (European 
Pharmacopoeia 6.1, 2007). 
 
According to the manufacturer, the particle size of the nifedipine powder was less than 5 
µm in at least 85% of particles, and all the particles were under 20 µm. The manufacturer 
stated that the particle size of nifedipine in the tablet form was 7–13 µm, with not more 
than 20% of particles over 25 µm and at most 2% of the particles over 30 µm. Adalat 10 
mg retard could be pulverized, because it does not contain any technological structure 
which is not allowed to be crushed; the retard effect is based on the particle size and the 
low water solubility of the drug. 
4.1.2 Excipients 
 
Lactose (Lactosum monohydricum Ph.Eur. parve granules, Pharmatose® 80 mesh, DMV 
International) and microcrystalline cellulose (Avicel® PH-102, FMC Corporation or 
Emcocel® 90M, Tamro, Finland) were used as excipients in the oral solid dosage forms. 
Hypromellose (Metocel E50LV, Ph.Eur. 50 mPa.s, University Pharmacy, Finland) was 
used as the suspending agent in sterile water, which was used as a vehicle in 
suspensions. 
 
The solubility of lactose in 20°C water is 1 in 5.2 4 (Rowe et al., 2007). Lactose is not 
hygroscopic. The bulk density of Pharmatose® 80 mesh (DMV International) is 0.76 
mg/cm3 and the tapped density is 0.91 mg/cm3. According to the supplier, 70–90% of the 
particles were under 250 µm, <20% were under 100 µm and >95% were under 315 µm.  
 
Microcrystalline cellulose is practically insoluble in water (Rowe et al., 2007). The bulk 
density for microcrystalline cellulose is 0.29 g/cm3 for Emcocel® 90M and 0.32 g/cm3 for 
Avicel® PH-102. The tapped densities are 0.35 g/cm3 for Emcocel® 90M and 0.48 g/cm3 
for Avicel® PH-102 (Allen, 2002; Rowe et al., 2007). Not more than 8% of the particles are 
retained in a mesh size of 250 µm and not less than 45% are retained in a mesh size of 
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74 µm (Rowe et al., 2007). Since it is a hygroscopic ingredient, it absorbs moisture from 
the air and thus has to be dispensed in tightly closed containers (Allen, 2002). 
 
In Europe, grades of hypromellose are distinguished by appending a number indicative of 
the apparent viscosity in millipascal seconds of a 2% w/w solution measured at 20°C 
(Martindale, 2002). Hypromellose powder absorbs moisture from the atmosphere (Rowe 
et al., 2007). It is soluble in cold water, forming a viscous colloidal solution. The pH of 1% 
w/w aqueous solution is 5.5–5.8. Aqueous solutions may be sterilized by autoclaving, but 
on cooling must the coagulated polymer be redispersed by shaking. 
 
Adalat® retard tablets contain microcrystalline cellulose as a lubricant and disintegrant, 
maize starch as a binder, filler and disintegrant, lactose monohydrate as a filler, 
polysorbate 80 as a wetting agent and non-ionic surfactant, and magnesium stearate as a 
lubricant (Pharmaca Fennica, 2007; Rowe et al., 2007). The filmcoating contains 
polyethylenglycol (macrogol) 4000 as a plasticizer in conjunction with film-forming 
hypromellose, white pigment titanium dioxide (E171) as a coating agent, opacifier and 
colouring pigment, and red ferrous oxide (E172) as colouring agent to increase the 
stability of light-sensitive active ingredient.  
4.1.3 Packaging materials 
 
Nifedipine powders were packed in waxed, sealed powder papers, which were sized at 47 
x 30 mm (Paperityö, Helsinki, Finland).  
 
Hard gelatine capsules, volumes of 0.50 ml (clear number 1, Tamro, Finland), 0.30 ml 
(clear number 3, Gallipot, USA), and 0.21 ml (white number 4, Gallipot, USA) were used 
as the packaging material in the capsules, whose contents were emptied for use.  
 
Unit doses of nifedipine suspension were packed into 2 ml disposable syringes (Discardit, 
Becton Dickinson, Spain). Syringes were made of polyethylene (PE) and polypropylene 
(PP). The syringes were capped (Kombi-Stropfen, Clinico, Bad Hersfeld, Germany).  
 
To protect the nifedipine from light all the dosage units were packed in black plastic bags 
(Amerplast, Ikaalinen, Finland). The containers and packing materials used in the study 
were the same as the actual packaging used for storage and distribution. 
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4.1.4 Standards for high performance liquid chromatography (HPLC) 
 
Nifedipine stock solution, 1 mg/ml, was prepared from analytical grade nifedipine 
(nifedipine N-7634, Sigma Chemical Company, St. Louis, MO). HPLC-grade methanol 
(Lab-Scan, Dublin) was used to dilute the stock solution to standard concentrations of 5 
µg/ml, 7 µg/ml (II,III, IV), 10 µg/ml, 12 µg/ml (II, III, IV), 13 µg/ml (I) and 15 µg/ml (II, III, 
IV). 
 
In studies II, III and IV, bupivacaine hydrochloride (Astra, Finland) was used as an internal 
standard. 
 
4.2 Methods 
4.2.1 Preparation of oral powders (I, IV) and capsules (IV) 
 
Nifedipine oral powders and capsules were prepared by mixing five crushed and carefully 
ground 10-mg nifedipine tablets and the geometric amounts of either lactose or 
microcrystalline cellulose to achieve a final nifedipine concentration of 1.0 mg/unit. 
Nifedipine tablets were crushed in a mortar with a pestle. Crushed nifedipine tablets and 
nifedipine drug powder were examined in the scanning electron microscope (Jeol JSM-35 
Scanning microscope, Tokyo, Japan). Nifedipine was always handled in a dimly lit room. 
 
The resulting powder was divided into portions in powder papers or capsule shells. To 
prepare oral powders, the powder mixture was individually weighed into portions of 50 mg, 
100 mg, 300 mg or 500 mg. The powders were packed in waxed powder papers. While 
preparing capsules, hard gelatine capsules of sizes 1 (0.50 ml), 3 (0.30 ml) and 4 (0.21 
ml) were filled with the resulting powder using a hand operated capsule filler. 
4.2.2 Testing of nifedipine at various hypromellose concentrations and preparation 
of suspension (II, III) 
 
To find the optimal resuspendible and dose-accurate combination, different concentrations 
of hypromellose colloids were compounded with both nifedipine drug powder and crushed 
tablets. Hypromellose concentrations of 0.5%, 1.0%, 1.5%, 2.0%, 2.5% and 3.0% were 
used. The samples were taken with 2 ml disposable syringes, which are also used in 
practice. 
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The following tests were applied: 
1. visual observation of sedimentation after one month of storage at room temperature 
(22–23°C, relative humidity (RH) of 60–72%), 
2. measurement of the nifedipine concentration from the upper, middle and lower parts of 
the suspension vial 15 seconds after redispersion of the sediment by inverting the vial 
10 times, 
3. measurement of the nifedipine concentration from the middle part of the vial 
immediately, 1 min and 2 min after shaking, and 
4. measurement of nifedipine concentration and resuspending properties after one month  
of storage in a unit dose syringe at room temperature (22–23°C, 60–72% RH). 
 
Hypromellose powder was wetted with hot (80–90°C) w ater and cold (5°C) water was then 
added and the hypromellose solution was allowed to cool in ice water until it was 
thoroughly hydrated. Hypromellose solution was sterilized in a autoclave. 
 
Nifedipine oral suspensions were prepared using nifedipine tablets or drug powder. The 
tablets were allowed to soak in hypromellose solution and then crushed. A small amount 
of hypromellose was ground into the drug powder. A uniform paste was prepared by 
adding geometric amounts of hypromellose solution. This was packed into a single unit 
syringes with a cap. 
4.2.3 Content uniformity (I, II, IV) 
 
The content uniformities of the nifedipine oral powders and suspensions were determined 
by a method described in the European Pharmacopoeia (European Pharmacopoeia 3rd 
ed, 1996; European Pharmacopoeia 5.5, 2006). The test for content uniformity is based 
on the assay of the individual contents of active substance of a number of dosage units to 
determine whether the individual contents are within the limits set. Ten dosage units were 
taken at random and individual contents of nifedipine were measured using high 
performance liquid chromatography. The preparation complied with the test if not more 
than one of the 10 individual contents was beyond ±15% of the average content, and if 
none were beyond ±25% of the average content. 
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4.2.3.1 HPLC-assay 
 
Nifedipine amount was measured by a reproducible and validated stability-indicating 
HPLC method (Hagan, 1994). A forced photodegradation experiment on the nifedipine 
substance was performed in order to develop a validated HPLC-method. This was 
conducted by exposing nifedipine drug powder and crushed tablets to light of different 
wavelengths until significant degradation occurred. The stability-indicating capability of the 
HPLC method was verified by heating the nifedipine solution and a crushed tablet which 
were first mixed with either 1 M hydrochloric acid or 1 M sodium hydroxide (Mehta, 1993). 
The selectivity and specificity of the HPLC method were also confirmed by using liquid 
chromatography-mass spectrometry (Helin, 1995). The system precision of the HPLC 
method was examined and the correlation coefficients were determined (Hagan, 1994). 
 
The concentrations of nifedipine formulations were estimated by peak height (I) or area (II, 
III, IV) relative to the drug substance using HPLC with UV detection at a wavelength of 
238 nm. The HPLC system used in each of the studies is described in publications I, II 
and IV with a reverse phase C18 column being used. The mobile phase consisted of 68–
70% methanol in 30–32% deionized distilled water which contained 0.1M ammonium 
acetate and 0.1% triethylamine. The pH was adjusted to 5.8. The flow rate was 1.0 
ml/min. Bupivacaine was used as an internal standard (II, III, IV).  
 
Each randomly selected sample of nifedipine oral powder, capsule or suspension was 
emptied carefully into a sample bottle. Methanol was added to a total volume of 10.0 ml. 
Ultrasound sonication (I, IV), centrifuging (II, III) and shaking (IV) were used to ensure 
dissolution of nifedipine in methanol. To prepare a sample solution, a 1000 µl of the 
resulting nifedipine solution was taken and diluted 1:10 with methanol. This solution as 
such (I) was assayed by HPLC, or a 750 µl the aliquot of solution was mixed with 250 µl of 
bupivacaine which acted as an internal standard solution (II, III, IV), and then assayed. All 
the samples were prepared in a dimly lit room and protected from light. 
4.2.4 Chemical stability studies (I, III) 
 
To study the stability the samples were stored under three controlled conditions: 1) at 
room temperature (21–23°C, 43–47% RH (I), 60–72% RH  (III)) protected from light, 2) in a 
refrigerator (5–7°C, 60–66% RH (I), 67–77% RH (III) ) protected from light, and 3) at room 
temperature (21–23°C, 60–72%RH (I), 58–62% RH (III) ) exposed to artificial daylight. 
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Temperatures of the room and refrigerator were adjusted according to the European 
Pharmacopoeia (European Pharmacopoeia 3rd ed, 1996; European Pharmacopoeia 5.5, 
2006).  
 
It is difficult to establish the actual exposure of nifedipine products to light during practical 
usage. In tests simulating glass-filtered daylight, ‘artificial daylight’ fluorescent tubes were 
used. The spectrum of artificial full colour daylight was measured and it resembled the 
spectrum of mixed artificial light of the room and natural daylight coming through a 
window. Solid drug substances were spread across the folded powder paper. The 
samples from the powder papers and oral syringes were spread in a single layer to 
provide a maximum area of exposure to the light source. The spectral distribution of the 
light sources used was determined (III). The illumination of the sample area was 
measured with a lux meter and was found to be 400 lux at a distance of 60 cm from the 
lamp (I, III). 
 
Nifedipine powder papers were stored for either 12 months protected from light or for 5 
days when exposed to light. Nifedipine suspensions made in the optimal vehicle, 1% 
hypromellose, were stored after for 28 days protected from light or for 7 days when 
exposed to artificial daylight. 
 
Samples were removed after the pre-determined period of storage and were analysed to 
assay the nifedipine concentration and to assess the degree of photodegradation. An 
HPLC-method was used to determine the nifedipine concentration as previously 
described. Drugs were considered stable if they retained ≥ 90% of the initial drug 
concentration (Mehta, 1993). 
4.2.5 Physical stability studies (II, III) 
 
Both nifedipine 1 mg/ml suspension and the optimal vehicle, hypromellose 1.0% solution, 
were tested for density (Mohr Westphal scale, Germany), pH (Mettler Toledo 320, 
Switzerland), osmolality (Osmostat Auto-Osmometer, Japan), viscosity (Falling Sphere 
Viscometer and Haake Rotovisco RV 2,, Gebrüder Haake, Germany), surface tension 
(Krüss Interfacial Tensiometer, GWB, Germany) and organoleptic properties. Nifedipine 
suspensions were tested immediately after preparation and on days 14 and 28 of storage 
at either room temperature (22°C, 60–72% RH) or in a refrigerator (6°C, 67–77% RH). 
Hypromellose 1.0% solution was studied at the time of preparation, before and after 
steam sterilization and at 3, 6 and 12 months. The products were tested at 20°C, because 
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changes in temperature can affect viscosity and other physical characteristics. The 
equipment was calibrated at intervals as recommended by manufacturer. 
4.2.6 Microbiological stability studies (II, III) 
 
Although the European Pharmacopoeia does not require that an oral preparation should 
be microbe free, this is, of course, preferable for critically ill neonates. The microbiological 
stability of nifedipine suspensions and 1.0% hypromellose solution were investigated by 
using the European Pharmacopoeia method (European Pharmacopoeia 3rd ed, 1996). 
Antimicrobial properties of the nifedipine solution were studied. The microbiological 
stability of nifedipine suspensions was determined immediately after preparation and on 
days 7, 14, 21 and 28 days after storage either protected from light at room temperature 
(22°C, 60–72% RH) or in a refrigerator (6°C, 67–77%  RH) began. The sterility of the 
hypromellose 1.0% solution was tested after steam sterilization, and after 3, 6 and 12 
months of storage at room temperature (22°C, 60–72%  RH) using the method of direct 
inoculation (European Pharmacopoeia 3rd ed, 1996). Fastidious anaerobe broths, tryptic 
soy broths and sabouraud broths were used as media. 
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5 RESULTS 
 
5.1 Particle size characteristics of nifedipine drug powders and crushed tablets 
 
The particle size of nifedipine drug powder and crushed Adalat® 10 mg retard tablet was 
characterized visually in a scanning electron microscope to obtain information about  the 
properties of the powder mixture and suspensions. Nifedipine drug powder was relatively 
uniform in particle size whereas crushing of nifedipine tablets produced particles less than 
100 µm that differed in size and shape (Figures 4 and 5). The particle size, which was less 
than 100 µm, was about the same particle size of the excipients and thus prevented 
stratification between large and small particles. 
 
 
Figure 4. Nifedipine drug powder as viewed in a scanning electron microscope (II). Scale 
bar is 100 µm. 
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Figure 5. Nifedipine tablet crushed with a mortar and pestle and examined in a scanning 
electron microscope (II). Scale bar is 100 µm. 
 
 
5.2 Testing of nifedipine at various hypromellose concentrations (II) 
 
Nifedipine suspensions that were made from hypromellose concentrations of 0.5%, 1.0% 
and 1.5% were more flocculated and easier to redisperse than the other suspensions (II, 
Table 1). Suspensions made from nifedipine drug powder were more difficult to redisperse 
than the suspensions made from crushed tablets, but the concentrations after mixing were 
close to each other. As a result, hypromellose 1.0% was selected as a vehicle for 
suspensions with both drug powders and crushed tablets. 
 
5.3 Content uniformity (I, II, IV) 
 
The content uniformities of nifedipine powders, capsules and suspensions complied with 
the test specifications. The mean ± SD content of nifedipine theoretical content 1.0 mg 
was 0.92 ± 0.03 mg in powders (I), and 1.06 ± 0.05 mg and 1.09 ± 0.05 mg in nifedipine 
suspensions (II) made from crushed tablets and drug powders with 1.0% hypromellose, 
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respectively. The largest deviations from the mean content were 4.6% for powders, and 
8.5% and 9.2% for suspensions. No remarkable differences were noted between 
hypromellose concentrations 0.5%, 1.0% and 1.5% or between nifedipine drug powders 
and crushed tablets. 
 
Comparison between the different amounts of lactose monohydrate and microcrystalline 
cellulose as excipients in oral powders and capsules indicated that content uniformity 
remained acceptable although content was reduced down to about 85–90% of the 
theoretical value. In powders weighing 100 mg and 50 mg, the content was below 80% of 
the theoretical value both with lactose and microcrystalline cellulose (Figures 6 and 7). 
The nifedipine content was over 80% of the theoretical value in small capsules where the 
amount of the excipients were quite similar. 
 
It was noticed that about 8% of the nifedipine amount of 1.0 mg was lost during the 
preparation and storage of powder papers (I). About 75% of that was found from the 
emptied powder papers. Minor amounts were found in the mortar and pestle and the other 
equipment used. 
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Figure 6. Nifedipine content in oral powders and emptied capsules number 1 (400 mg), 3 
(230 mg) and 4 (160 mg) filled with lactose monohydrate. Theoretical amount of nifedipine 
was 1 mg. Mean values are shown (n = 10). 
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Figure 7. Nifedipine content in oral powders and emptied capsules number 1 (200 mg), 3  
(130 mg) and 4 (80 mg) filled with cellulose microcrystalline. Theoretical amount of 
nifedipine was 1 mg. Mean values are shown (n = 10). 
 
 
5.4 Chemical stability studies (I, III) 
 
At least 92% of the initial concentration of nifedipine remained in the powders that were 
protected from light and stored at room temperature or in refrigerator for one year. In 
suspensions compounded from crushed tablets or drug powder, 95% and 93% of the 
mean nifedipine concentrations remained in the suspensions stored at room temperature, 
throughout the 28-day study period. When stored in the refrigerator, 91% and 92% 
remained, respectively. No evidence of the presence of degradation products was 
observed. 
 
Significant degradation of nifedipine was observed in the powders exposed to light. 
Photodegradation of the nifedipine exceeded 20% within three hours and 40% within six 
hours and was essentially complete after three days. In suspensions made from tablets, 
photodegradation exceeded 26% within three hours and 40% within six hours, and was 
essentially complete after 7 days.  Nifedipine powder in suspensions degraded more 
rapidly: 30% within three hours and nearly all of the active drug has disappeared after 
three days. 
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5.5 Physical stability studies (II, III) 
 
At the end of the study intervals, the samples of drug-free hypromellose solution 1% and 
nifedipine suspensions (1 mg/ml) in 1% hypromellose solution protected from light were 
examined for any changes in their physical properties. Hypromellose solution 1% 
remained physically stable during the study period of 12 months (II, Table 5). The pH, 
viscosity, density, osmolality and surface tension of the nifedipine suspensions prepared 
both from tablets and drug powder, remained fairly stable over 28 days (III, Tables 3–4). 
Visual inspections revealed no change in colour during the study period. The colour of the 
nifedipine suspensions changed when they were exposed to light for 7 days. 
 
5.6 Microbiological stability studies (II, III) 
 
No microbiological contamination was observed in any samples of drug-free hypromellose 
1% during a period of 6 months (22–23°C). Because o f probable laboratory 
contamination, Propionebacterium was found in one of the samples at 12 months, but the 
duplicate test was sterile. 
 
The antimicrobial properties of nifedipine suspension 1 mg/ml were examined. Nifedipine 
suspension did not inhibit the growth of microbes (Staphylococcus aureus, Bacteroides 
fragilis, Candida albicans). In the study of the microbiological stability of nifedipine 
suspension 1 mg/ml, no bacterial or fungal growth was observed in suspensions during 
the 28 day study period.  
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6 DISCUSSION 
 
6.1 Nifedipine and excipients 
 
Nifedipine is commonly used cardiovascular drug for which no licensed liquid is available. 
A nifedipine formulation obtained from crushed solid dosage form may not be 
bioequivalent with the same dosage form swallowed whole (Standing and Tuleu, 2005). It 
is known that when nifedipine retard tablets are crushed, drug release and dissolution rate 
increase (Tuleu et al., 2005). However, the usual recommendation in hypertension is to 
give a modified release preparation to avoid large swings in blood pressure (Standing and 
Tuleu, 2005). Licensing of nifedipine allows adults the benefit of once daily dosing, 
decreased risk of adverse drug reactions and formalised post-marketing surveillance. 
Children, who need to be treated with the same drug, have to take a dose three times a 
day, and are exposed to potentially increased risk of adverse drug reactions because no 
sustained release formulation is available. 
 
To administer nifedipine orally to infants, one of the following methods may be used: 1) 
removal of nifedipine oily liquid from commercial soft capsules, 2) splitting of nifedipine 
retard tablets into segments, crushing the segment and administering it with food or 
beverages, 3) importing commercial drops of nifedipine 20 mg/ml, or 4) preparation of 
extemporaneous suspensions, powders or capsules from crushed retard tablets or drug 
powder (Tuleu et al., 2005). Unfortunately, nifedipine soft capsules of different brands 
contain different amounts of liquid and nifedipine drops are too concentrated. They both 
contain polyethylene glycols of low molecular weight as diluents, which might be harmful 
to infants. Splitting of tablets may lead to significant fluctuations in the administered dose. 
Thus, extemporaneous suspensions, powders or capsules are the choice to produce 
nifedipine drug products to infants. 
 
The selection of the appropriate excipients for extemporaneous preparation is the 
responsibility of the pharmacist. Adverse toxic effects have been reported in paediatric 
patients due to the use of inappropriate excipients. Properties of the excipients may have 
also an influence on the uniformity of content and on loss of drug substance during its 
dispensing. 
 
The ingredients in our nifedipine oral powder and capsule studies were selected because 
of their flow properties and particle size distribution. Both lactose and microcrystalline 
  
48
cellulose are widely used and safe excipients in solid oral pharmaceutical formulations. 
The ingredient used in the suspension study, hypromellose, also known as 
hydroxypropylmethylcellulose, is nonreactive and pH-neutral, and thus assumed to be 
suitable for neonatal use. While it was appreciated that pure hypromellose as a 
suspending agent would not to produce an ideal suspension but it was believed that the 
suspension would be accurate and safe to use also for neonates who have several 
restrictions on what excipients can be used. Hypromellose vehicle has also been reported 
to be suitable for administering nimodipine 60 mg via an oral syringe, in patients with 
acute subarachnoid haemorrhage (Soppi et al., 2007).  
 
Lactose is broken down after hydrolysis by intestinal lactase and absorbed (Pawar and 
Kumar, 2002). Unabsorbed lactose is converted to lactic acid, carbon dioxide and 
hydrogen gas by the intestinal flora, and this can acidify the bowel, increase the osmotic 
load and irritate the colon. The safety of lactose during the neonatal phase is still being 
debated, as preterm infants have diminished levels of the enzyme lactase (Guandalini et 
al., 2006). Lactase activity increases progressively in the fetal intestine through the third 
trimester and approaches its maximum expression at term. Very few preterm neonates 
born at 28 weeks' gestation and approximately 40% of infants born at 34 weeks' gestation 
have significant intestinal lactase activity. Lactose is also contraindicated in infants with 
galactosemia, a rare congenital disorder that results in accumulation of galactose-1-
phosphate, resulting in developmental delay, hepatic failure and cataracts (Pawar and 
Kumar, 2002).  
 
6.2 Content uniformity 
 
The content uniformity is a major factor if one wishes to assure repeatability of dosages 
and thus, the preparation of a safe and effective medication. Although the test of content 
uniformity is a requirement of European Pharmacopoeia (2007) and USP Pharmacists’ 
Pharmacopeia (2008) for oral powders, capsules and suspensions, results can seldom be 
found in peer-reviewed journals.  
 
Instead of the preparation of an extemporaneous product, tablet segments are sometimes 
used. According to our studies, better content uniformity is, however, achieved by 
extemporaneous preparation of oral solid or liquid dosage forms. Crushing of tablets is a 
critical point in the powder mass preparation. The grinding time and technique can 
influence the resulting homogeneity of the powder mixture by affecting the electrostatic 
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properties of the powder. It also has to be noted that particles may become segregated if 
they need to be stored before dispensing the doses. Thus, an awareness of this problem 
and professional skills are key factors in preparing extemporaneous medicines of good 
quality. 
 
Our results indicated that the loss of nifedipine during the preparation process may be 
considerable. On the average, content uniformity testing revealed 0.92 mg of nifedipine in 
the 1.0 mg powders. Three quarters of the missing amount was located on the emptied 
powder papers. In the oral powder study of Hepojoki (2008) significant loss of drug 
substance, dipyridamole, was also found: on average 3% of the drug was found to be 
adhering to the equipment used during its preparation, 4–15% on the powder papers and 
9–14% on the equipment used during administration. The amount of drug loss was 
dependent on the excipient used. 
 
We found that preparation of small capsules, such as size numbers 3 or 4 was acceptable 
when considering the average nifedipine content. Thus, 80 mg of microcrystalline 
cellulose or 160 mg lactose was sufficient. Instead, the amount of excipient in oral 
powders has to be higher, since the amount of recovered nifedipine decreased as the total 
mass of the prepared oral powder was 50 mg or 100 mg. Nifedipine recovery was nearly 
the same in all emptied capsules compared with emptied oral powders weighing 300 mg 
or more. The reason for that might be smaller area of the capsule shells compared to the 
sealed powder papers. 
 
A 1.0% solution of hypromellose was thick enough to reduce the rate of settling. 
Tötterman et al (1994) found that autoclaving decreased the viscosity of hypromellose-
E50 1.5–4.0% solutions and the decrease in viscosity increased with the increase in the 
concentration of hypromellose. According to our study, the viscosity of the hypromellose 
1.0% solution did not decrease remarkably during steam sterilisation, perhaps because of 
its low concentration.  
 
Nifedipine suspension, formulated with hypromellose 1.0% solution, remained sufficiently 
homogenous to permit the removal of the accurate dose after shaking. Our impression 
was that suspensions made from crushed tablet were easier to redisperse than 
suspensions made from drug powder, which may be because of the differences in the 
particle size. The particle size in drug powder was smaller than in crushed tablet. That 
may result in more closely packed sediment. Prefilled oral syringes assure the uniformity 
of doses and also represent a medication that is ready to use. Only a small amount of air 
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needs to be drawn into the syringe before administration to ensure the resuspension of 
the settled particles. Unit-dose packaging of nifedipine suspensions prevents 
microbiological contamination, which was found by Ghulam et al. (2007) in multidose 
extemporaneous preparations.  
 
6.3 Stability 
 
These formulations provided adequate stability of extemporaneously prepared and light-
protected nifedipine powders, capsules and suspensions for use in hospitalised patients. 
The investigated stability of the nifedipine formulations now means that the nifedipine 
preparations can be stored. The photodegradation of nifedipine was faster in suspensions 
made from drug powder than in those made from tablets because of light-protective effect 
of the excipients present in the tablets. Because these extemporaneously prepared 
nifedipine products are stable in the secondary package but unstable if it is not present, it 
is necessary to label products to prevent storage without secondary package. Tuleu et al. 
(2005) found that nifedipine in extemporaneous suspension (1 mg/ml) started to degrade 
after 15 min of exposure to light. 
 
Nahata et al. (2002) investigated the stability of nifedipine in two oral suspensions and 
found them to be stable up to three months with refrigeration and at room temperature in 
amber plastic bottles. The vehicles used in that study were methylcellulose 1% : simple 
syrup NF (1:13) and Ora Plus® : Ora Sweet® (1:1). Dentinger et al. (2003) found 
extemporaneously prepared nifedipine 10 mg/ml oral solution to be stable for at least 35 
days when stored in amber glass bottles at 22–25°C.  The solution was prepared from 
nifedipine powder with polyethylene glycol 400, glycerol, and peppermint oil. According to 
Table 2, sucrose from simple syrup, and sucrose, glycerol and methylparaben of Ora-
Sweet® and Ora-Plus®, and  polyethylene glycol, glycerol and peppermint oil might cause 
some adverse effects. Thus, it is recommended that these excipients should not be used 
in neonates and infants. 
 
One problem arising in stability testing of powder papers, capsules and dose syringes is 
that the analytical results tend to be more scattered because they are distinct dosage 
units rather than the true aliquots encountered with stability studies on drugs in solution. 
Thus, the uniformity of content has to be ensured.  
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6.4 Practical implications 
 
In practice, extemporaneous preparation is an acute multidisciplinary process where 
decisions are made in co-operation with physicians, pharmacists and nurses. At present, 
there are no comprehensive published standards, and therefore decisions in different 
steps of preparation process have to be made by using professional pharmaceutical skills. 
During this study, a management flow chart and decision pathway was created for solving 
the issues encountered in the production of extemporaneous oral preparations (Figure 8). 
Roles and responsibilities in different stages of the preparation process are presented in 
Table 3.  
 
In a ward setting, some problems may occur in administering the nifedipine powder 
through a nasogastric tube. However, the present studied nifedipine suspensions were 
found to flow easily through the small-bore nasogastric feeding tube, and no tube 
occlusion has been encountered. 
 
In routine work, photodecomposition might occur not only during storage but also during 
preparation and use of the product. To prevent photodegradation, correct handling and 
storage procedures of nifedipine preparations needs to be taught to nurses, other health 
care providers, and parents. Extemporaneous nifedipine single-dose preparations are 
simple to use also at home, and the stability of the drug is relatively good.  
 
Table 3. Model of roles and responsibilities in extemporaneous preparation in hospital 
pharmacy in Finland 
Handling state Chief 
pharma-
cist 
Pharma-
cist 
(master 
degree) 
Pharma-
cist 
(barchelor 
degree) 
Accredited 
technician 
Physi-
cian 
Ward 
nurse 
Order     R S 
Design of 
product 
 R RS  AC CI 
Formulation A R RS    
Preparation  AC R I   
Packaging and 
labelling 
 AC AC R   
Final check A RAC R I   
Dispensing  AC R SI   
R = responsible person, A = person to whom R is accountable, S = can be supportive, C = 
could be consulted, I = should be informed 
  
52
P
a
c
k
a
g
in
g
 a
n
d
 
la
b
e
lli
n
g
F
in
a
l 
c
h
e
c
k
 
(q
u
a
lit
y
 
c
o
n
tr
o
l)
D
e
s
ig
n
 o
f 
p
ro
d
u
c
t
F
o
rm
u
la
ti
o
n
P
re
p
a
ra
ti
o
n
O
rd
e
r
ORDER FOR PAEDIATRIC 
ORAL DRUG 
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Packaging Labelling
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Figure 8. Process of preparing extemporaneous oral preparations and decision-making  
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7 CONCLUSIONS  
 
According to these studies, the following conclusions are presented: 
 
1. Nifedipine capsules, whose contents are emptied prior to use, provide an alternative to 
oral powders in preparing paediatric medications. The content uniformities of the 
nifedipine capsules and oral powders made from crushed tablets with different 
amounts of lactose monohydrate or microcrystalline cellulose met the established 
requirements. However, the nifedipine amount was less than 80% of the theoretical 
value in oral powders of total weight 100 mg and 50 mg. 
2. Nifedipine 1.0 mg in 500 mg of a powder compounded extemporaneously from 
nifedipine tablets and lactose monohydrate was stable for up to one year when stored 
in waxed powder papers in black plastic bags at room temperature and in refrigerator.  
3. A 1.0% hypromellose solution had the best properties as a suspending agent for 1 
mg/ml nifedipine. Autoclaved drug-free hypromellose 1.0% solutions were 
microbiologically stable for at least 6 months.  
4. The content uniformity of the nifedipine suspension made from both crushed tablets 
and drug powder met the established requirements.  
5. Nifedipine unit-dose suspensions, packaged in capped syringes, were chemically, 
physically and microbiologically stable throughout the 4-week study period in oral 
syringes that were at room temperature or being refrigerated protected from light. 
6. When exposed to light, nifedipine in the powder or suspension degraded rapidly at 
room temperature. In all, 20–30% photodegradation of the nifedipine occurred within 
three hours. 
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